Regenxbio RGNX 深 沪
已收盘 10-02 16:00:00 美东时间
7.43
+0.010
+0.13%
华盛通- 最 高7.62
- 今 开7.58
- 成交量 103.69万股
- 最 低 7.36
- 昨 收 7.42
- 总市值 4.90亿
- 52周最高 16.19
- 市盈率 静 --
- 换手率 1.57%
- 52周最低 5.455
- 委 比 -87.73%
- 总股本 6601.32万
- 历史最高 85.10
- 量 比 0.63
- 振 幅 3.50%
- 历史最低 5.035
- 每 手 1
- 风险率 2.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Regenxbio rises on new director stock purchase
Regenxbio (RGNX) is up ~3% in Friday morning trading after recently appointed director Gregory Austin Ciongoli bought more than 102,000 shares valued at more than $949,000. An SEC filing shows that he...
08-28 21:57
美股大行评级 | 瑞杰金融维持英伟达"强力买入"评级，目标价从330美元升至352美元；瑞穗下调美光科技目标价从1375美元降至1300美元
今日重点评级关注：摩根大通：维持Ultragenyx Pharmaceutical"超配"评级，目标价从75美元升至80美元；瑞杰金融：维持英伟达"强力买入"评级，目标价从330美元升至352美元
08-26 08:37
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multip...
08-25 19:05
Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.
08-25 18:29
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatmen...
08-24 19:05
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
This HubSpot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst David Hynes downgraded Commerce.Com Inc (NASDAQ:CMRC) from Buy to Hold ...
08-07 19:54
Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12
Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:RGNX) from Overweight to Equal-Weight and maintains the price target from $12 to $12.
08-07 18:36
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments
REGENXBIO Inc. (NASDAQ:RGNX) on Saturday shared long-term clinical trial findings for its experimental gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) targeting wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR). Long-Term Efficacy In Wet AMD Treatment Data pres...
07-20 22:45
